Here's why AstraZeneca's shareholders can expect healthy returns from this $39 billion investment.
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Alexion Ph
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
Investors don't seem impressed with AstraZeneca's (LON: AZN) latest deal, which is also the biggest deal in the company's history.  Fundamental analysis: Hefty price paid The British-Swedish pharma g
Seeking Alpha Transcripts | Healthcare AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) Dec. 15, 2020 9:50 AM ET | | About: AstraZeneca PLC (AZN), AZNCF by: SA Transcr
WILMINGTON, Del., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ GS: ALXN) regarding possible breache
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. ("Alexi
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4%
The Nasdaq Composite looked to get back into record territory on Monday.
Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.

AstraZeneca: Starting The Acquisition Boom

12:06pm, Monday, 14'th Dec 2020
Over the weekend, AstraZeneca made a $39 billion offer to acquire Alexion Pharmaceuticals in a deal that looks like it will benefit both parties.
Alexion finally gets taken out.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca PLC (NASDAQ: AZN).
Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion. There
AstraZeneca is buying Alexion Pharmaceuticals for $39 billion in stock and cash, its largest deal ever. The transaction values Alexion at $175 a share, a 40% premium over its average price in the past
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE